154 related articles for article (PubMed ID: 22950787)
1. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.
Gupta AK; Verma AK; Kailashiya J; Singh SK; Kumar N
Platelets; 2012; 23(8):565-70. PubMed ID: 22950787
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
3. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin: a review.
Subbarayan S; Kipnes M
Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
7. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
8. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
[TBL] [Abstract][Full Text] [Related]
9. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
10. [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Oct; 68(10):504-10. PubMed ID: 24298724
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation.
White PC; Chamberlain-Shea H; de la Morena MT
J Diabetes Complications; 2010; 24(3):209-13. PubMed ID: 19854074
[TBL] [Abstract][Full Text] [Related]
12. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
14. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
[TBL] [Abstract][Full Text] [Related]
15. Clinical review of sitagliptin: a DPP-4 inhibitor.
Garg K; Tripathi CD; Kumar S
J Assoc Physicians India; 2013 Sep; 61(9):645-9. PubMed ID: 24772702
[TBL] [Abstract][Full Text] [Related]
16. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
Mohan V; Yang W; Son HY; Xu L; Noble L; Langdon RB; Amatruda JM; Stein PP; Kaufman KD
Diabetes Res Clin Pract; 2009 Jan; 83(1):106-16. PubMed ID: 19097665
[TBL] [Abstract][Full Text] [Related]
18. New treatments for type 2 diabetes--the DPP4 inhibitors.
Gadsby R
Prim Care Diabetes; 2007 Dec; 1(4):209-11. PubMed ID: 18632049
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
Cai B; Katz L; Alexander CM; Williams-Herman D; Girman CJ
Int J Clin Pract; 2010 Nov; 64(12):1601-8. PubMed ID: 20946268
[TBL] [Abstract][Full Text] [Related]
20. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
